Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ReShape Lifesciences Inc.

    NASDAQ: RSLS · Real-Time Price · USD
    4.20
    -0.05 (-1.18%)
    At close: Jun 06, 2025, 3:59 PM
    4.01
    -4.52%
    After-hours: Jun 06, 2025, 05:56 PM EDT

    ReShape Lifesciences Statistics

    Share Statistics

    ReShape Lifesciences has 738.28K shares outstanding. The number of shares has increased by 0.13% in one year.

    Shares Outstanding

    n/a
    		 738.28K

    Shares Change (YoY)

    n/a
    		 0.13%

    Shares Change (QoQ)

    n/a
    		 2.45%

    Owned by Institutions (%)

    n/a
    		 0.04%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 7,682

    FTD / Avg. Volume

    n/a
    		 0.47%

    Short Selling Information

    The latest short interest is 43.98K, so 5.96% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 43.98K

    Short % of Shares Out

    n/a
    		 5.96%

    Short % of Float

    n/a
    		 5.96%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -8.06 and the forward PE ratio is null. ReShape Lifesciences's PEG ratio is 0.09.

    PE Ratio

    n/a
    		 -8.06

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 7.18

    Forward PS

    n/a
    		 0.3

    PB Ratio

    n/a
    		 -227.22

    P/FCF Ratio

    n/a
    		 -12.99

    PEG Ratio

    n/a
    		 0.09
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for ReShape Lifesciences.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.92, with a Debt / Equity ratio of -3.82.

    Current Ratio

    n/a
    		 0.92

    Quick Ratio

    n/a
    		 0.43

    Debt / Equity

    n/a
    		 -3.82

    Debt / EBITDA

    n/a
    		 -0.15

    Debt / FCF

    n/a
    		 -0.22

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $470,941.18

    Profits Per Employee

    n/a
    		 $-419,411.76

    Employee Count

    n/a
    		 17

    Asset Turnover

    n/a
    		 1.67

    Inventory Turnover

    n/a
    		 1.2

    Taxes

    Income Tax

    n/a
    		 39K

    Effective Tax Rate

    n/a
    		 -0.55%

    Stock Price Statistics

    The stock price has increased by -98.73% in the last 52 weeks. The beta is 1.94, so ReShape Lifesciences's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.94

    52-Week Price Change

    n/a
    		 -98.73%

    50-Day Moving Average

    n/a
    		 8.79

    200-Day Moving Average

    n/a
    		 94.16

    Relative Strength Index (RSI)

    n/a
    		 39.05

    Average Volume (20 Days)

    n/a
    		 1,628,216

    Income Statement

    In the last 12 months, ReShape Lifesciences had revenue of 8.01M and earned -7.13M in profits. Earnings per share was -13.83.

    Revenue

    n/a
    		 8.01M

    Gross Profit

    n/a
    		 5.06M

    Operating Income

    n/a
    		 -6.67M

    Net Income

    n/a
    		 -7.13M

    EBITDA

    n/a
    		 -6.67M

    EBIT

    n/a
    		 -6.67M

    Earnings Per Share (EPS)

    n/a
    		 -13.83
    Full Income Statement

    Balance Sheet

    The company has 693K in cash and 967K in debt, giving a net cash position of -274K.

    Cash & Cash Equivalents

    n/a
    		 693K

    Total Debt

    n/a
    		 967K

    Net Cash

    n/a
    		 -274K

    Retained Earnings

    n/a
    		 -642.7M

    Total Assets

    n/a
    		 4.79M

    Working Capital

    n/a
    		 -397K
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -4.43M and capital expenditures 0, giving a free cash flow of -4.43M.

    Operating Cash Flow

    n/a
    		 -4.43M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -4.43M

    FCF Per Share

    n/a
    		 -8.59
    Full Cash Flow Statement

    Margins

    Gross margin is 63.17%, with operating and profit margins of -83.29% and -89.06%.

    Gross Margin

    n/a
    		 63.17%

    Operating Margin

    n/a
    		 -83.29%

    Pretax Margin

    n/a
    		 -88.57%

    Profit Margin

    n/a
    		 -89.06%

    EBITDA Margin

    n/a
    		 -83.29%

    EBIT Margin

    n/a
    		 -83.29%

    FCF Margin

    n/a
    		 -55.3%

    Dividends & Yields

    RSLS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for RSLS.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 9, 2025. It was a backward split with a ratio of 1:25.

    Last Split Date

    n/a
    		 May 9, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:25

    Scores

    Altman Z-Score

    n/a
    		 -190.35

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist